Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Thursday, November 26, 2020

Etanercept

alkiviadis.1961 shared this article with you from Inoreader

Abstract

Etanercept is a soluble dimeric fusion protein that was the first anti-tumor necrosis factor (TNF-α(alpha)) drug to be approved for the treatment of psoriasis and psoriatic arthritis. It is administered subcutaneously by self-injection. As with other biologic drugs for psoriasis, etanercept offers a targeted approach to treatment that lacks end organ side effects of traditional systemic therapies such as methotrexate, cyclosporine, or acitretin. With over 8 years of postmarketing experience in psoriasis (and over 14 years since approval for moderate to severe RA in 1998), a large body of safety data exists for etanercept. Here, we review the safety and efficacy of etanercept in the treatment of plaque psoriasis and psoriatic arthritis, with emphasis on published Phase 3 and Phase 4 clinical trial data. Safety considerations, recommended monitoring, and studies of combination therapy are also discussed.

View on the web

No comments:

Post a Comment